Hormonal
Long-term endurance exercise prevents age-related declines in insulin sensitivity and mitochondrial oxidative capacity, rendering these functions comparable to those of young sedentary individuals.
If you are an older adult concerned about metabolic health, habitual endurance exercise (cycling or running, ~1 hour, 6 days/week) can normalize your insulin sensitivity and mitochondrial function to levels seen in young sedentary people. Focus on consistency rather than intensity; the key is long-term adherence, not short-term bursts.
The results demonstrate that reduced insulin sensitivity is likely related to changes in adiposity and to physical inactivity rather than being an inevitable consequence of aging. The results also show that regular endurance exercise partly normalizes age-related mitochondrial dysfunction...
Why this rating
Cross-sectional study with rigorous metabolic clamping and molecular analysis, but lacks longitudinal causality proof for the specific 'prevention' claim.
Source
Endurance Exercise as a Countermeasure for Aging
Ian R. Lanza et al. · Diabetes · 2008
DOI 10.2337/db08-0349
More from this paper
- Long-term endurance exercise elevates SIRT3 expression to levels comparable to young individuals, potentially linking exercise benefits to caloric restriction pathways.Good
- While endurance exercise normalizes most mitochondrial protein expression and ATP production capacity, it does not fully restore mitochondrial DNA (mtDNA) abundance or all nuclear transcription factors to young levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →